Abstract
INTRODUCTION
Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis even when treated. Therefore, finding an effective treatment has been a challenge for the last 30 years [1] . The available, albeit limited, data on the treatment of patients with MPM suggest that multimodality therapy leads to better results compared with other strategies. Surgical treatment options for MPM include extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D), both of which can be incorporated into multimodality regimens involving neoadjuvant or adjuvant chemotherapy and adjuvant radiotherapy [2] .
Because of the diffuse growth pattern and the lack of surgical margins, microscopic complete resection is theoretically impossible. Thus, a macroscopic complete resection (MCR) is the most one can expect to achieve with surgical resection, even though the optimal cytoreductive procedure is still controversial [3, 4] . EPP is a well-codified operation, and for many years, it was considered the best surgical option to achieve MCR and to obtain a survival advantage [3] . The definition of P/D, on the other hand, has varied according to the surgical technique, therapeutic intent and clinical indications [5, 6] . P/D was initially proposed as a valid cytoreductive surgical alternative to EPP for patients who were unwilling to undergo EPP or who did meet the indications for EPP [7] [8] [9] . Recently, 2 metaanalyses comparing the 2 surgical procedures suggested significantly lower perioperative mortality and morbidity rates and a trend towards longer survival for patients who had P/D in comparison with EPP [10, 11] .
In 2011, the consensus report by the International Mesothelioma Interest Group and the International Association for the Study of Lung Cancer (IASLC) recommended that the surgical procedures be classified into 3 well-defined categories: (i) EP/D, (ii) P/D and (iii) partial pleurectomy [12] . The potential benefits of surgery are still unclear from the literature, especially concerning P/D, and few authors have evaluated the clinical impact and outcome of patients who have had different types of P/D. The aim of the study was to evaluate the outcome after multimodality treatment of MPM involving different types of P/D and to analyse the prognostic factors.
MATERIALS AND METHODS
Data from 314 patients affected by histologically proven MPM and operated on between 1 January 1 2007 and 11 October 2014 were prospectively collected from 11 Italian centres and reviewed.
Demographics and clinical preoperative, operative and postoperative data were considered for statistical analysis. Preoperative studies included total body computed tomography (CT) scans and/or positron emission tomography CT scans, electrocardiograms, echocardiograms and spirometry with blood gas analysis. Tumour, node and metastasis (TNM) and International Mesothelioma Interest Group staging systems were used to define the extent of the disease.
Patients underwent the multimodality approach based on a single-centre protocol comprising induction chemotherapy and/ or adjuvant treatment with surgical resection.
All patients had a pleurectomy through a posterolateral thoracotomy. All centres reviewed the operative charts so they could define the surgical procedures according to the International Mesothelioma Interest Group/International Association for the Study of Lung Cancer classification [12] system, which provides 3 categories depending on the surgical technique: (i) extended P/D (EP/D): parietal and visceral pleurectomy to remove all gross tumour, with resection of the diaphragm and/or pericardium; (ii) P/D: parietal and visceral pleurectomy to remove all gross tumour, without resection of the diaphragm or pericardium; and (iii) partial pleurectomy: partial removal of parietal and/or visceral pleura for diagnostic or palliative purposes, leaving gross tumour behind.
The choice of EP/D versus P/D was determined by the macroscopic absence/presence of diaphragmatic and pericardial involvement by the disease: In both procedures, an MCR was the goal.
Operative complications were separated into major (acute respiratory distress syndrome, pneumonia, bronchopleural fistula, reintubation, placement of tracheostomy, pulmonary embolus, empyema, sepsis, myocardial infarction, ventricular arrhythmia requiring treatment, return to operating room, acute renal failure, chylothorax, deep venous thrombosis and others) and minor complications (atrial arrhythmia requiring treatment, anaemia, urinary tract infection, delirium, prolonged air leaks and others) for the purpose of analysis. Major complications were considered those that required a second surgical look or that were associated with the risk of death or a significantly prolonged hospital stay due to the need for intensive medical support.
For induction and/or adjuvant chemotherapy, a platinumbased regimen with gemcitabine or pemetrexed was used for 3 to 4 cycles. Adjuvant radiotherapy was not standardized and varied from radiation limited to the surgical scars or a boost to the macroscopic residual tumour (20-30 Gy) to standard radiation treatment, helical tomotherapy or intensity-modulated radiation therapy (dose range 40-50 Gy).
Patients were followed up with clinical checks, imaging studies (CT scan and/or positron emission tomography CT scan) and a phone interview every 4 months for the first year and then every 6 months for the following years. Survival was calculated from the date of surgery to the date of last follow-up or death. The following parameters were considered and evaluated in the statistical analysis: age, gender, side of the disease, histology, preoperative treatments, type of surgical intervention, postoperative treatments, T and N status and pathological stage.
Statistical analysis
In the statistical description, data are expressed as absolute numbers, percentages and mean or median values. The association between qualitative variables was verified by means of the v 2 test or the Fisher test, as appropriate. The Kaplan-Meier method was used to model survival during follow-up to estimate the median survival time and the 95% confidence interval (CI) and to compare survival curves with the log-rank test. Simple Cox proportional hazard regression was used to calculate the unadjusted hazard ratio (HR) for prognostic factors. A forward stepwise Cox regression model, with entry and stay of variables showing a significance level of at least 0.1, was applied to obtain adjusted HRs. All statistical analyses were performed using SAS statistical software release 9.3 (SAS Institute, Cary, NC, USA) with the significance level set at P < 0.05.
RESULTS
Patients' characteristics as a whole population and divided by the type of surgical intervention are summarized in Table 1 . One hundred sixty-two (51.6%) patients had EP/D; 115 (36.6%) patients underwent P/D; and 37(11.8%) received only a partial pleurectomy. Thirty-and 90-day mortality rates were 2.2% (n = 7) and 3.5% (n = 11), respectively. The 30-day mortality rates for EP/ D, P/D and partial pleurectomy were not significantly different (2.5% vs 1.7% vs 2.7%, respectively; P = 0.88 by the Fisher's exact test); a similar result was observed regarding the 90-day mortality rates (3.1% vs 3.5% vs 5.4%, respectively; P = 0.75 by the Fisher's exact test). Causes of perioperative (30-day) death were massive pulmonary embolism (n = 2), bleeding (n = 1), myocardial infarction (n = 1), stroke (n = 1), ventricular arrhythmia (n = 1) and unknown (n = 1). The overall major morbidity rate was 15.9% (n = 50), with a significantly (P < 0.001) higher rate for EP/D (17.9%) and P/D (16.5%) compared with partial pleurectomy (5.4%); the type and distribution of major complications based on the different surgical approaches are reported in Table 2 After the operation, 123 (39.2%) patients were submitted to adjuvant radiotherapy with different treatment modalities (conventional radiotherapy, intensity-modulated radiation therapy and helical tomotherapy); 102 (32.5%) had radiotherapy limited to the surgical scars or to a boost to macroscopic residual disease and 89 (28.3%) did not receive any radiation treatment. A platinum-based adjuvant chemotherapeutic regime was administered to 75 (23.9%) patients.
At the end of the follow-up (median 15.5 months, range 1-118 months) period, 142 (45.2%) patients were alive; 157 (50%) had died; and 15(4.8%) were lost after a median time of initial clinical observation of 5 (range 1-13) months ( Table 2) .
The median overall survival after the operation was 23.0 (95% CI: 19.6-29.1) months, with 3-and 5-year survival rates of 37.5% and 21%, respectively (Fig. 1) . The results of the statistical analysis of prognostic factors are reported in Table 3 . On univariable analysis, the left-sided disease (P = 0.02), the partial pleurectomy intervention (P = 0.003), the pathological T4-stage (P = 0.0002), the positive nodal status (P = 0.03) and the pathological disease Partial pleurectomy (N = 37; 11.8%) Stage III or IV (P = 0.002) were factors that significantly predicted a poorer prognosis (Figs 2-5) .
The multivariable Cox proportional hazard regression model found pathological disease Stage III-IV (P = 0.004, HR: 1.34; 95% CI: 1.09-1.64), EP/D and P/D (P = 0.006, HR for EP/D: 0.46; 95% CI: 0.29-0.74; HR for P/D: 0.52; 95% CI: 0.31-0.87), left-sided disease (P = 0.01, HR: 1.52; 95% CI: 1.09-2.12) and pathological T4 status (P = 0.0003, HR: 1.38; 95% CI: 1.14-1.66) to be independent significant predictors of survival.
DISCUSSION
The most effective treatment for MPM is controversial: It often involves a coordinated multimodality approach that incorporates surgery, systemic therapy (chemotherapy) and radiation [2] . Although the role and effectiveness of surgery in the treatment of MPM are still unclear, many surgeons think that the goal of every operation is to leave the patient in a state of no evidence of disease by accomplishing an MCR with the goal to improve longterm outcome in these patients [13] . The best way to accomplish this goal is, however, controversial, because a surgical standard of care for patients with MPM has not been established. Two surgical approaches are used: The lung-sacrificing operation (EPP) is highly standardized and the lung-sparing operation (P/D) is wildly variable with respect to extent (completeness of resection) but also with nomenclature [5] . The first report of pleurectomy in the treatment of MPM was by Martini et al. [6] in 1975, who described outcomes of parietal pleurectomy followed by external radiation and systemic chemotherapy in 14 patients: the median survival was 16 months. A year later, this series was expanded to include 33 patients with MPM who had a median survival of 21 months [14] . Since then, a number of non-randomized studies have demonstrated the feasibility and the safety of P/D for MPM with several different multimodality schemes involving induction and adjuvant treatments [5, 15, 16] . A potential disadvantage of P/D is the theoretically less cytoreductive capacity compared with EPP; in particular, the effectiveness and radicality of P/D in patients with advanced MPM is one of the main controversial points. Friedberg et al. [17] reported an MCR rate of 97% and a median survival of 21 months in their series of radical pleurectomy with intraoperative photodynamic therapy for advanced MPM. On the basis of their results, they theorized that MCR could be achieved with radical pleurectomy in all patients with MPM in whom MCR could be achieved with EPP. A similar finding was reported by Nakas et al. [18] in locally advanced (T3-4) non-sarcomatoid MPM. Bolukbas et al. [19] , on the other hand, reported in patients with Stage III MPM treated with radical pleurectomy a lower MCR rate (61.9%) and a relatively high surgical mortality rate (4.8%), with a median survival of 21 months, comparable with the results from previous studies. The greatest recognized advantage of P/D is the lower rates of postoperative morbidity and mortality compared with EPP. Moreover, the preservation of the ipsilateral lung parenchyma has the potential to enhance quality of life and may allow greater tolerance of more aggressive adjuvant treatments, both initially and at the time of recurrence. Two recent meta-analyses of a large number of studies comparing P/D to EPP suggest that P/D, in the context of multimodality therapy, is associated with a 2.5-fold lower short-term mortality rate (perioperatively and within 30 days), a greater than 50% reduction in postoperative morbidity, with an equivalent, if not greater, median overall survival [10, 11] . When analysing these reviews, however, one should take into account the biases that go into selecting a patient for one or the other procedure, the retrospective nature of most of the studies, the imbalanced patient characteristics and the varying adjuvant treatments used. In a recent editorial, Raja Flores [20] pointed out that attention to the recent general shift in surgery for MPM from EPP to P/D after a large comparative multicentre study by experienced mesothelioma surgeons failed to demonstrate significant survival differences between the 2 procedures [9] . He commented that 'the data suggest that the primary goal of surgery should not just be to obtain an MCR (R1) at the expense of pneumonectomy. More realistic goals should include the removal of as much tumor as possible while avoiding pneumonectomy, lung re-expansion, prevention of fluid reaccumulation, while minimizing morbidity and mortality. On the basis of the currently available data the equation tips in favor of P/D rather than EPP'. Many MPM centres in Europe and some in North America and Japan are currently performing P/D with curative intent [9, 21, 22]; moreover, Variables with P < 0.10 based on univariable calculations were entered into the multivariable models. In multivariable models, criteria for entering and staying were 0.10 and 0.05, respectively. b Due to high correlation (Spearman's R = 0.80; P < 0.0001), pT stages and pathological stage were entered into separate models. AIC for best model showed similar values: Model I AIC = 1473.421; Model II AIC = 1464.277. a MARS-II trial is currently underway to compare P/D versus best medical therapy [23] .
If one looks at the current literature, one notes that pleurectomy-related procedures in various studies differ between institutions in terms of therapeutic intent, surgical technique and definition [5, [9] [10] [11] 18] . To date, no prospective study has evaluated the operative results in terms of the extent of the pleurectomy. A recent systematic review by Cao et al. [5] assessed the outcome of 1916 patients with MPM by analysing 34 studies and stratifying the surgical approach by the extent of the pleurectomy. Although detailed statistical analyses were not possible due to a lack of data, median overall and disease-free survival outcomes appeared to be longer in patients who had EP/D compared with those who had P/D and partial pleurectomy (the reported middle 2 quartile survival ranges were 15-25 months for EP/D, 12-18 months for P/D and 9-13 months for partial pleurectomy). The possible explanation may be related to the increased ability to achieve MCR by removing the diaphragm and pericardium when these areas are affected by tumours. Additionally, the results of this review suggested a similar perioperative mortality outcome between different P/D techniques, but a trend towards higher morbidity and length of hospitalization for patients who underwent EP/D was shown.
The results of our series are slightly different because the shortand long-term outcomes were similar between EP/D and P/D. Indeed, patients receiving EP/D or P/D (with no difference between these 2 procedures: log-rank test P = 0.75) had a significant survival advantage compared with those who had a partial pleurectomy. In our study, we observed a perioperative mortality rate of 2.2%, which was slightly lower than the average 4% (range, 0-25%) reported in the review of Teh et al. [24] , who analysed the data of 1270 patients undergoing P/D for MPM from 26 series.
No differences in perioperative mortality rates between the 3 procedures were observed in our series, but a significantly higher rate of major complications was associated with EP/D and P/D compared with partial pleurectomy. The poor survival results observed in the group of patients receiving partial pleurectomy raise the question as to the opportunity and ability to perform this type of operation. Also, the MesoVATS trial found no benefit for minimally invasive partial cytoreduction compared with pleurodesis [25] . These authors reported a 50-60% 1-year overall survival rate in both groups (median survival, 13 months), with worse survival in higher risk patients undergoing thoracoscopic partial pleurectomy. The palliative role of partial pleurectomy is debatable and not clearly demonstrated in the literature in terms of the improvement of quality of life, effectiveness for pain and control or reduction of pleural effusion.
Our study confirmed that the selection criteria are crucial in MPM patients: As in the majority of published series [2, 3, 9, 13, 26] , advanced T status and advanced pathological stage were significant predictors of worse survival. Non-epithelial histology, male gender and nodal involvement were also associated with a poor outcome.
We also found that the side on which the tumour occurs was a predictor of prognosis, with the right-sided operation associated with a significantly prolonged survival. The reasons are unclear. We may hypothesize that the performance of cytoreduction on the right side, where the pleural cavity is larger than on the left, could be better, just as the potential for effective adjuvant radiotherapy is lower on the left side due to the presence of the heart. 
